Shots:
- The two companies will develop and launch precision medicine strategies for CV, renal, and metabolic diseases. The first stage in the collaboration will use KidneyIntelX to improve outcomes for patients with CKD and its complications, in coordination with the Mount Sinai Health System
- The first stage will assess the impact of AI-enabled in vitro diagnostic solutions to optimize the utilization of therapies in CKD under current SOC protocols. The study will evaluate uptake and adherence to new potassium-binding agents in patients with CKD and hyperkalemia with its anticipated results in 2021
- The studies will be conducted in coordination with the Mount Sinai Health System, where KidneyIntelX testing and care management software are currently being deployed for commercial clinical use
Click here to read full press release/ article | Ref: PRNewswire | Image: Renalytixa
